Pharmaceuticals - Indian - Bulk Drugs & Formln Lrg
Sun Pharmaceutical Industries Ltd is commonly known as Sun Pharma. It is a leading player in the pharmaceutical sector. Headquartered in Mumbai, Maharashtra, the company specializes in manufacturing and marketing formulations and active pharmaceutical ingredients (APIs). Sun Pharmaceutical Industries Ltd was founded in 1983 and it has been in business for a long time. This showcases their strong and consistent presence in the industry. The main products offered by the company include branded generics and over the counter (OTC) medications. These products cover a broad spectrum of chronic and acute therapies. Read More...
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Total Revenue | 49,887.17 | 44,394.10 | 39,729.96 | 34,357.31 | 33,489.09 |
Total Expenses | 38,304.96 | 34,814.22 | 30,681.82 | 27,251.80 | 28,218.86 |
Profit Before Tax | 11,087.89 | 9,408.43 | 4,481.32 | 2,799.37 | 5,009.59 |
Profit After Tax | 9,648.44 | 8,560.84 | 3,405.82 | 2,284.68 | 4,186.79 |
Operating Profit after Depreciation | 11,820.68 | 9,751.88 | 9,175.49 | 7,246.94 | 5,572.96 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Fixed Assets | 27,457.53 | 28,429.93 | 23,154.45 | 22,183.29 | 23,408.34 |
Total Non Current Assets | 42,029.77 | 40,881.65 | 34,943.17 | 37,224.65 | 36,598.30 |
Total Current Assets | 43,433.11 | 39,861.94 | 34,864.60 | 30,442.08 | 31,654.16 |
TOTAL ASSETS | 85,462.88 | 80,743.59 | 69,807.77 | 67,666.73 | 68,252.46 |
Total Shareholder's Fund | 63,666.75 | 55,995.38 | 48,011.22 | 46,462.78 | 45,264.45 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Net Cash from Operating Activities | 12,134.98 | 4,959.33 | 8,984.54 | 6,170.37 | 6,554.77 |
Net Cash used in Investing Activities | -762.90 | -7,219.92 | -5,555.86 | 406.53 | -2,225.32 |
Net Cash used in Financing Activities | -6,710.16 | 2,376.07 | -5,193.46 | -5,980.48 | -5,715.14 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Total Revenue | 20,828.65 | 21,141.43 | 16,782.86 | 14,308.12 | 14,042.85 |
Total Expenses | 17,159.98 | 16,462.59 | 14,655.47 | 13,362.99 | 10,789.85 |
Profit Before Tax | 3,449.65 | 1,741.05 | 306.86 | 855.57 | 3,253 |
Profit After Tax | 2,858.18 | 1,690.72 | -99.99 | 842.40 | 3,211.14 |
Operating Profit after Depreciation | 4,452.75 | 5,151.02 | 2,515.49 | 1,212.65 | 3,661.01 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Fixed Assets | 8,114.61 | 9,235.71 | 10,182.48 | 10,299.97 | 5,441 |
Total Non Current Assets | 26,152.25 | 24,543.74 | 31,061.73 | 31,004.71 | 26,469.21 |
Total Current Assets | 14,912.54 | 16,443.75 | 9,703.75 | 12,730.08 | 11,941.12 |
TOTAL ASSETS | 41,064.79 | 40,987.49 | 40,765.48 | 43,734.79 | 38,410.33 |
Total Shareholder's Fund | 23,694.40 | 23,748.36 | 24,587.95 | 26,938.47 | 24,396.22 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Net Cash from Operating Activities | -292.42 | 507.08 | 7,636.36 | -416.51 | 1,305.85 |
Net Cash used in Investing Activities | -265.35 | -685.64 | -2,697.04 | 1,452.47 | 1,483.04 |
Net Cash used in Financing Activities | 473.95 | 169.31 | -4,870.85 | -999.73 | -2,871.15 |
Particulars (in ₹ Cr.) | 2024-12 | 2024-09 | 2024-06 | 2024-03 | 2023-12 |
---|---|---|---|---|---|
Total Revenue | 13,675.46 | 13,291.39 | 12,652.75 | 11,982.90 | 12,380.70 |
Total Expenses | 9,666.44 | 9,352.43 | 9,045.13 | 8,947.75 | 8,903.87 |
Profit Before Tax | 3,476.40 | 3,597.88 | 3,423.50 | 2,815.52 | 3,000.35 |
Profit After Tax | 2,917.54 | 3,030.67 | 2,871.25 | 2,666.59 | 2,568.03 |
Operating Profit after Depreciation | 4,474.64 | 4,292.96 | 4,140.17 | 3,641.09 | 3,727.03 |
Particulars (in ₹ Cr.) | 2024-12 | 2024-09 | 2024-06 | 2024-03 | 2023-12 |
---|---|---|---|---|---|
Total Revenue | 6,191.81 | 5,127.71 | 4,498.07 | 5,639.14 | 5,073.75 |
Total Expenses | 4,488.34 | 3,789.09 | 3,737 | 3,745.61 | 3,714.75 |
Profit Before Tax | 1,264.93 | 895.64 | 257.92 | 1,401.78 | 751.47 |
Profit After Tax | 1,181.05 | 863.29 | 237.82 | 867.60 | 721.31 |
Operating Profit after Depreciation | 1,771.86 | 1,424.92 | 843.81 | 2,012.41 | 1,435.80 |
₹10.5/Share
Company | Price | Market Cap (in ₹ Cr) |
---|---|---|
Sun Pharmaceuticals Industries Ltd | ₹1,704.65 | ₹4,09,002.64 |
Divis Laboratories Ltd | ₹5,836.45 | ₹1,54,939.41 |
Cipla Ltd | ₹1,459.05 | ₹1,17,834.93 |
Torrent Pharmaceuticals Ltd | ₹3,011.50 | ₹1,01,918.27 |
Dr Reddys Laboratories Ltd | ₹1,195.85 | ₹99,784.59 |
Mankind Pharma Ltd | ₹2,396.85 | ₹98,886.10 |
03 Feb 2025, 04:58 pm
The pharma major's consolidated net profit increased 15.04% to Rs 2,903.38 crore on 10.46% rise in revenue from operations to Rs 13,675.46 crore in Q3 FY25 over Q3 FY24.
31 Jan 2025, 04:13 pm
Of Rs.10.50 per share
31 Jan 2025, 03:26 pm
On 31 January 2025
20 Jan 2025, 09:48 am
16 Jan 2025, 02:30 pm
View More